CD274 and neoplasm: Similarly, like PD-L1, the value of TMB as a biomarker may be limited.191,242 Following neo-adjuvant immunotherapy, an increase in T-cell clonality or special TIME subtypes248 has been observed to be correlated with a lower percentage of residual tumor at surgery, supported by the NEOSTAR244 and NADIM study249 findings.